Biologics (Monoclonal Antibodies) CDMOs in China
10 published
10 published CDMOs match Biologics (Monoclonal Antibodies) in China.
Locations in this set include China, United States, Singapore, Japan, South Korea, and United Kingdom.
Capabilities that show up most often in this set: CMC Analytical Development, Formulation Development, Process Development, Sterile Fill-Finish & Aseptic Manufacturing, and Monoclonal Antibody (mAb) Manufacturing.
Matching companies
Altruist BiologicsGlobal CDMO offering end-to-end development and GMP manufacturing for monoclonal antibodies, bispecific antibodies, fusion proteins, recombinant proteins, and antibody-drug conjugates, with facilities in Suzhou and Hangzhou featuring up to 20,000-liter bioreactors.
Boston Institute of Biotechnology, LLCFull-service CDMO offering cGMP and non-GMP mammalian, microbial, gene therapy, and cell therapy manufacturing from preclinical to commercial scale, with bioreactor capacity up to 50,000L.
CatalentGlobal CDMO providing end-to-end contract development and manufacturing for pharma, biotech, and consumer health. Delivers 60+ billion doses annually across small molecules, biologics, cell & gene therapies, and clinical supply.
PharmaronPremier life science CRO and CDMO offering integrated R&D and manufacturing across drug discovery, preclinical, clinical development, and commercialization for small molecules, biologics, and cell & gene therapies. 25,000+ employees across China, US, and UK.
Piramal Pharma SolutionsCDMO specializing in HPAPIs, ADCs, peptides, vaccines, and biologics with 4,700+ team members across 15 global sites and 500+ customers. Offers integrated development and manufacturing with backward integration capabilities and global program management.
ProBioProBio is a leading global CDMO subsidiary of GenScript Biotech Corporation, providing end-to-end services for biologics and cell & gene therapy (CGT) from drug discovery through commercialization.
Stevanato GroupLeading global provider of integrated drug containment, drug delivery, and diagnostic solutions with 75+ years' experience in glass primary packaging, contract manufacturing, and analytical services across development, clinical, and commercial stages.
Vetter PharmaIndependent CDMO specialist in aseptic fill-finish, drug product development, analytical services, and combination product assembly with 76 years of experience and 7,300+ employees globally.
WuXi VaccinesGlobal CDMO specializing in end-to-end vaccine and prophylactic antibody development and manufacturing across mammalian, viral, and microbial platforms with GMP-certified facilities and over 550 million doses delivered.
WuXi XDCWuXi XDC is a leading CRDMO offering integrated discovery, development, and cGMP manufacturing services for antibody drug conjugates (ADCs) and bioconjugates, with proximately located facilities that reduce development timelines and costs.
Markdown mirror: /modalities/biologics-monoclonal-antibodies/china.md